tiprankstipranks
Medicenna’s Bizaxofusp Boosts Brain Cancer Survival
Company Announcements

Medicenna’s Bizaxofusp Boosts Brain Cancer Survival

Medicenna Therapeutics Corp (TSE:MDNA) has released an update.

Don't Miss our Black Friday Offers:

Medicenna Therapeutics Corp. has presented promising clinical data at the ASCO 2024 showing that its drug, bizaxofusp, significantly increases survival rates for patients with recurrent glioblastoma. Compared to a matched external control, bizaxofusp nearly doubled the median overall survival time and halved the risk of death. These results support bizaxofusp as a potential new standard of care that doesn’t require IL-4R expression testing for efficacy.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedicenna Showcases Promising Results and Strong Financials
TipRanks Canadian Auto-Generated NewsdeskMedicenna to Present Innovative Cancer Data at Conferences
TipRanks Canadian Auto-Generated NewsdeskMedicenna Reports Promising Results with MDNA11
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App